Topic : TKIs

Other Topics :

Evaluating high-dose Gleevec

Before the second-generation TKIs (Sprycel, Tasigna, Bosulif) became available, the best option for people with an inadequate response to Gleevec was to give more Gleevec. So many studies used twice the usual dose (or 800 mg per day).
Continue Reading →

Most people will achieve treatment response targets

A new study has looked at the proportion of people with CML who achieve the key treatment milestones, which represent the optimal response to a medication at different time points (Jain and colleagues. Br J Haematol 2016;173:114-126). These milestones are developed by research groups
Continue Reading →

Generic imatinib: patient advocacy groups’ recommendations

Gleevec has been the cornerstone of CML treatment for the past 15 years. However, the introduction of a generic formulation (imatinib) has made patients and physicians uncertain about the medications that are being used, according to The CML Advocates Network, a network of CML patient
Continue Reading →

ASCO 2016: What are the benefits of a “deep response”?

During treatment with a TKI (tyrosine kinase inhibitor), regular tests are needed to ensure that you’re responding to the medication. The amount of disease suppression is reported according to the reduction in leukemia proteins (or transcripts) compared to a reference. So a reduction
Continue Reading →

ASCO 2016: Stopping treatment – findings of the largest study to date

Treatment-free remission – the possibility that some people may be able to stop taking their medication – is the hottest topic in CML research. The idea is that if you can achieve a deep enough response to a medication, the leukemia will be so suppressed that it won’t be able
Continue Reading →

“Deep molecular response” – how an idea evolved

TKI (tyrosine kinase inhibitor) therapy established a new standard for what medications could achieve in the treatment of CML (and set the bar for all cancer therapies). With TKIs, the goal posts shifted, but what constitutes a success has continued to evolve over time. The most recen
Continue Reading →

Can diabetes drugs help cure CML?

Tyrosine kinase inhibitors (TKIs, e.g. Gleevec, Tasigna, Sprycel, Bosulif, Iclusig) transformed the treatment of CML when they were introduced at the beginning of the 21st century. These medications target the leukemia gene that induces white blood cells to proliferate, effectively su
Continue Reading →

6 Key Questions about CML Treatment

After being diagnosed with chronic myelogenous leukemia, you and your doctor will need to make some decisions about the treatments you’ll need to keep your disease under control. The following are some of the most important questions about CML medications and how medical research has
Continue Reading →

What if treatment doesn’t work?

The development of Gleevec in 2001 revolutionized the treatment of CML. But the medication – although highly effective – won’t work in everyone, and some people may develop resistance to the drug. One reason for resistance is mutations, and over 80 different mutations have now been de
Continue Reading →

TKIs in people with liver or kidney disease

Clinical trials of medications generally exclude people with medical conditions other than the condition being studied, so little is known about whether these treatments are safe in a wide range of people. This issue is especially important in CML, because the disease affects older pe
Continue Reading →